John Newman, Ph.D. joined Canaccord Genuity in January 2013 and provides coverage of both the Biotechnology and Specialty Pharmaceuticals sectors. He has over eight years in equity research, with five as a senior analyst. Prior to Canaccord Genuity, John was a director at JMP Securities covering Specialty Pharmaceuticals and Biotechnology and a director at Citadel Securities covering Biotechnology. Before Citadel, John was a director covering Specialty Pharmaceuticals and Biotechnology at Oppenheimer and Company. John began his career on Wall Street at Merrill Lynch. John undertook a postdoctoral fellowship at University of Wisconsin Madison following his PhD where he also took several business courses in finance and accounting. He received a PhD from the University of Maryland in chemistry and a BS in chemistry from Loyola University.